CLINICAL IMPLICATIONS OF NIVOLUMAB IN CANCER IMMUNOTHERAPY
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Poster
- By: KUCUK, Esra (Hacettepe University Faculty of Pharmacy, Clinical Pharmacy, Ankara, Turkey)
- Co-author(s): Esra KUCUK
Ecz. Burcu Kelleci, Hacettepe Universitesi Eczacilik Fakultesi Klinik Eczacilik Anabilim Dali
A cancer treatment recently focuses on immunotherapy such as nivolumab, ipilimumab and pembrolizumab.
We searched through the Pub-Med database (between 2010-2015) by using nivolumab and immunotherapy as keywords.
Nivolumab is administered via iv infusion over an hour at the dose of 2-3mg/kg for every 2-3 weeks. Drug must be constituted with 0,9%.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.